Literature DB >> 1742357

Effect of ADP-ribosylation and phosphorylation on the interaction of elongation factor 2 with guanylic nucleotides.

A Marzouki1, B Sontag, J P Lavergne, C Vidonne, J P Reboud, A M Reboud.   

Abstract

Samples of unmodified EF-2, EF-2 ADP-ribosylated with diphtheria toxin and NAD, and/or phosphorylated using ATP and the Ca(2+)-calmodulin dependent kinase III partially purified, were irradiated at 254 nm with 32P-labeled GDP or GTP, and analyzed by one- and two-dimensional gel electrophoresis. By this method we showed that unmodified EF-2 formed a stable complex with GDP but not with GTP, whereas phosphorylated EF-2 and ADP-ribosylated + phosphorylated EF-2 formed stable complexes even in the absence of irradiation, with GTP but not GDP. ADP-ribosylated EF-2 did not form stable complexes with either GDP or GTP. Prior ADP-ribosylation of EF-2 increased its ability to the phosphorylated. These results show that the structures of the two domains containing diphtamide 715 and the phosphorylatable threonines (between Ala 51 and Arg 60) are interdependent; modifications of these residues induce different conformational changes of EF-2 which alter the interactions of the factor with guanylic nucleotides as well with ribosomes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1742357     DOI: 10.1016/0300-9084(91)90159-x

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  3 in total

Review 1.  Peptide-chain elongation in eukaryotes.

Authors:  C G Proud
Journal:  Mol Biol Rep       Date:  1994-05       Impact factor: 2.316

Review 2.  Transformation, translation and TRAIL: an unexpected intersection.

Authors:  Shai White-Gilbertson; Semyon Rubinchik; Christina Voelkel-Johnson
Journal:  Cytokine Growth Factor Rev       Date:  2008-04       Impact factor: 7.638

3.  Modes of action of ADP-ribosylated elongation factor 2 in inhibiting the polypeptide elongation cycle: a modeling study.

Authors:  Kevin C Chen; Honglin Xie; Yujie Cai
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.